Skip to main content
Premium Trial:

Request an Annual Quote

VitaPath Genetics Lands $6M Equity Investment

NEW YORK (GenomeWeb News) – Molecular diagnostics developer VitaPath Genetics has raised $6 million in a private equity financing that was led by MDV-Mohr Davidow Ventures and included an investment from X/Seed Capital.

The company is developing a genetic test for spina bifida, a birth defect that affects the spine and which can be avoided with high doses of folic acid therapy.

The company plans to use the Series A financing to complete the validation of this first assay and to prepare for its commercial launch.

VitaPath Genetics CEO Bruce Cohen said in a statement that the firm's "unique approach to discovery and validation" will enable physicians to "identify and safely remediate mutations that would otherwise impair birth."

"Whereas most medicine is delivered after the fact, VitaPath provides actionable diagnostics to identify and prevent those most at risk from developing a disease or condition," MDV Partner Michael Goldberg added.

As part of the financing, Goldberg and X/Seed's Michael Borrus took seats on the firm's board of directors.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.